



TREATMENT WITH LONSURF

A guide for helping patients and caregivers during their treatment journey

INDICATIONS

LONSURF is a prescription medicine used:

- alone or in combination with the medicine bevacizumab to treat adults with colorectal cancer:
 - that has spread to other parts of the body, **and**
 - who have been previously treated with certain chemotherapy medicines
- alone to treat adults with a kind of stomach cancer called gastric cancer including adenocarcinoma of the gastroesophageal junction:
 - that has spread to other parts of the body, **and**
 - who have been previously treated with at least 2 types of treatment which included certain medicines

It is not known if LONSURF is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LONSURF may cause serious side effects, including:

- **Low blood counts.** Low blood counts are common with LONSURF and can sometimes be severe and life-threatening. LONSURF can cause a decrease in your white blood cells, red blood cells, and platelets.

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

About this guide

Hearing that a treatment has stopped working is never easy – but LONSURF® (trifluridine and tipiracil) tablets [LON-serf] is a prescription medicine that may offer another option to treat your colon, rectal, or stomach cancer.

Whether you have been prescribed LONSURF or just want to know more about it, this brochure is for you. It contains helpful information on:

- **What LONSURF is and how it might be able to help**
- **Common side effects with LONSURF**
- **Ways to help manage these side effects**
- **How to take LONSURF**
- **Ways to better prepare for healthcare provider visits**

The information in this booklet is not a substitute for your healthcare provider's advice. Always ask your healthcare provider any questions you may have about LONSURF and colon, rectal, or stomach cancer.

You can learn more at [LONSURF.com](https://www.lonsurf.com)

IMPORTANT SAFETY INFORMATION

- **Low blood counts (continued).** Low white blood cells can make you more likely to get serious infections that could lead to death. Your healthcare provider should do blood tests before you receive LONSURF, at day 15 during treatment with LONSURF, and as needed to check your blood cell counts. Your healthcare provider may lower your dose of LONSURF or stop LONSURF if you have low white blood cell or platelet counts

About LONSURF

LONSURF alone or with bevacizumab is FDA approved for use in patients:

- Living with **colon or rectal cancer** that has spread to other parts of the body
- Who previously have been treated with or cannot receive certain chemotherapy medicines
- Who now may need another option

LONSURF alone is also FDA approved for use in patients:

- Living with **stomach cancer** that has spread to other parts of the body
- Who previously have been treated with or cannot receive certain chemotherapy medicines
- Who now may need another option

LONSURF includes two medicines in the same tablet



- **Trifluridine** may help prevent tumor growth by interfering with the tumor's DNA
- **Tipiracil** helps trifluridine work longer



If you have colon or rectal cancer, LONSURF may be used together with bevacizumab (also referred to by the brand name Avastin[®]), which may help slow or stop blood supply to the tumor. You may have previously received bevacizumab as part of an earlier line of therapy.


Please see Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets

How LONSURF® (trifluridine and tipiracil) tablets can help

The **SUNLIGHT clinical trial** was a study of 492 patients that looked at the effectiveness and safety of LONSURF used together with bevacizumab compared to LONSURF alone for patients who had already received at least 2 types of treatment for their advanced colorectal cancer. The primary objective was overall survival. Some key secondary objectives were progression-free survival and the time to deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS).

Median overall survival




Overall survival is the time from when the patient starts treatment until they pass away. Patients taking LONSURF with bevacizumab had a median overall survival of **10.8 months** compared to **7.5 months** in the patients receiving only LONSURF – a **3.3-month improvement**. That means half of the patients in the group that received LONSURF with bevacizumab lived less than 10.8 months but the other half lived longer than that.



Learn more about how
LONSURF with bevacizumab
can make a difference

Median progression-free survival (PFS)



Progression-free survival is a measure of how long someone is on treatment before their cancer starts to grow. Patients taking LONSURF with bevacizumab had a median progression-free survival of **5.6 months** compared to **2.4 months** in the patients receiving only LONSURF – a **3.2-month improvement**.



You may also be prescribed LONSURF on its own. LONSURF was initially approved for treatment based on the results of the **RECOURSE clinical trial**, a study of 800 patients where LONSURF demonstrated a median overall survival of **7.2 months** compared to **5.2 months** in patients who received placebo.

IMPORTANT SAFETY INFORMATION

Tell your healthcare provider right away if you get any of the following signs and symptoms of infection during treatment with LONSURF: fever, chills, or body aches.

Please see additional Important Safety Information throughout and full [Prescribing Information](#).


Lonsurf[®]
(trifluridine and tipiracil) tablets

Measuring daily function

ECOG Performance Status score is a way to measure how well a patient is functioning in daily life, including things like taking care of themselves, walking around, or working. On the scale, 0 means someone is fully active and has no restrictions while 5 means they have passed away. So, the lower your ECOG Performance Status score, the better.

Score	ECOG Performance Status
0	Fully active
1	Ambulatory and able to carry out light work but restricted in strenuous activity
2	Bedbound less than 50% of waking hours and capable of self-care
3	Bedbound more than 50% of waking hours and capable of limited self-care
4	Bedbound, completely disabled and incapable of self-care
5	Deceased

Median time to ECOG PS score increasing to 2 or more



In the LONSURF[®] (trifluridine and tipiracil) tablets + bevacizumab group, the median time to ECOG Performance Status score going from 0 or 1 to 2 or more was **9.3 months**. The LONSURF-only group had a median time of **6.3 months**. So patients who received LONSURF + bevacizumab stayed at a lower, better, ECOG Performance Status longer than patients who received only LONSURF.



You can learn more about colon or rectal cancer through these organizations

Colontown

Visit colontown.org
or call 1-410-881-3160

Colorectal Cancer Alliance

Visit ccalliance.org
or call 1-877-422-2030

Fight Colorectal Cancer

Visit fightcolorectalcancer.org
or call 1-877-427-2111

GI Cancers Alliance

Visit gicancersalliance.org
or call 1-646-598-2001

The Raymond Foundation

Visit TheRaymondFoundation.org
or call 1-646-598-2001

CancerCare®

Visit cancercares.org
or call 1-800-813-HOPE (4673)

Cancer Support Community

Visit cancersupportcommunity.org
or call 1-888-793-9355

IMPORTANT SAFETY INFORMATION

Before taking LONSURF, tell your healthcare provider about all of your medical conditions, including if you:

- Have kidney or liver problems
- Are pregnant or plan to become pregnant. LONSURF can harm your unborn baby


Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf®
(trifluridine and tipiracil) tablets

How LONSURF® (trifluridine and tipiracil) tablets can help

The **TAGS clinical trial** was a study of 507 patients that looked at the effectiveness and safety of LONSURF compared to placebo for patients who had already received at least 2 types of treatment for their advanced stomach cancer. The primary objective was overall survival. Some key secondary objectives were progression-free survival (PFS) and time to deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS).

Median overall survival



Overall survival is the time from when the patient starts treatment until they pass away. Patients taking LONSURF had a median overall survival of **5.7 months** compared to **3.6 months** in the patients receiving only placebo. That means half of the patients in the group that received LONSURF lived less than 5.7 months but the other half lived longer than that.

Median progression-free survival (PFS)

Progression-free survival is a measure of how long someone is on treatment before their cancer starts to grow. Patients taking LONSURF had a median progression-free survival of **2.0 months** compared to **1.8 months** in the patients receiving only placebo.

Median time to ECOG PS score increasing to 2 or more

Patients taking LONSURF took **4.3 months** for their ECOG PS to go from 0 or 1 to 2 or more vs **2.3 months** in the patients receiving only placebo. Please see **page 6** to learn more about ECOG PS.



You can learn more about stomach cancer through these organizations

Debbie's Dream Foundation

Visit debbiesdream.org
or call 1-855-475-1200

Gastric Cancer Foundation

Visit gastriccancer.org

GI Cancers Alliance

Visit gicancersalliance.org
or call 1-646-598-2001

Hope for Stomach Cancer

Visit stocan.org
or call 1-424-239-9943

No Stomach for Cancer

Visit nostomachforcancer.org
or call 1-608-692-5141

The Raymond Foundation

Visit TheRaymondFoundation.org
or call 1-646-598-2001

CancerCare®

Visit cancercares.org
or call 1-800-813-HOPE (4673)

Cancer Support Community

Visit cancersupportcommunity.org
or call 1-888-793-9355

IMPORTANT SAFETY INFORMATION

- **Females who can become pregnant:** Your healthcare provider will do a pregnancy test before you start treatment with LONSURF. You should use effective birth control during and 6 months after the last dose of treatment with LONSURF. Tell your healthcare provider immediately if you become pregnant

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf®
(trifluridine and tipiracil) tablets

How to take LONSURF® (trifluridine and tipiracil) tablets

LONSURF tablets, whether prescribed alone or along with bevacizumab, are swallowed whole (not crushed, split, or chewed):

2x Twice a day with food



The type of food does not matter

LONSURF comes in 2 strengths: **15-mg** and **20-mg** tablets.



15-mg tablet



20-mg tablet

Tablets shown are not actual size.

Actual tablet size is 7 mm for 15-mg dose and 8 mm for 20-mg dose.

LONSURF 28-day dosing schedule

- You will take LONSURF twice a day (with morning and evening meals) for 5 days, and then rest for the next 2 days. This goes on for 2 weeks. Then you will not take LONSURF for 2 weeks (14 days). This completes the 28-day LONSURF treatment cycle
- This is repeated for as long as your healthcare provider says. Always follow all of your healthcare provider's directions carefully



For the majority of patients with colorectal cancer, LONSURF may be prescribed to be used with bevacizumab. **Bevacizumab is given as an infusion once every 2 weeks (on Days 1 and 15 of your LONSURF treatment cycle)** by a doctor or nurse.



Scan the QR code to learn more about how to take LONSURF, or visit LONSURF.com/taking-lonsurf/how-to-take-lonsurf

Tracking your treatment with LONSURF



Morning
daily dose



Evening
daily dose



Infusion dose of bevacizumab
(if prescribed)

Day 1: AM dose PM dose IV dose	Day 2: AM dose PM dose	Day 3: AM dose PM dose	Day 4: AM dose PM dose	Day 5: AM dose PM dose	Day 6: LONSURF break	Day 7: LONSURF break
Day 8: AM dose PM dose	Day 9: AM dose PM dose	Day 10: AM dose PM dose	Day 11: AM dose PM dose	Day 12: AM dose PM dose	Day 13: LONSURF break	Day 14: LONSURF break
Day 15: LONSURF break IV dose	Day 16: LONSURF break	Day 17: LONSURF break	Day 18: LONSURF break	Day 19: LONSURF break	Day 20: LONSURF break	Day 21: LONSURF break
Day 22: LONSURF break	Day 23: LONSURF break	Day 24: LONSURF break	Day 25: LONSURF break	Day 26: LONSURF break	Day 27: LONSURF break	Day 28: LONSURF break

Your healthcare provider may prescribe a morning and evening daily dose of LONSURF that requires you to take a combination of 15-mg and 20-mg tablets at the same time.

Use the digital calendar at [LONSURF.com/mycalendar](https://lonsurf.com/mycalendar) to help you keep track of your treatment. Your healthcare provider may give you a treatment calendar as well.

IMPORTANT SAFETY INFORMATION

- **Males**, while on treatment and for 3 months after your last dose of LONSURF, you should use a condom during sex with female partners who are able to become pregnant. Tell your healthcare provider right away if your partner becomes pregnant while you are taking LONSURF

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets

Other things to keep in mind about taking LONSURF® (trifluridine and tipiracil) tablets

- Wash your hands after handling LONSURF. Even though it is a pill, it is still chemotherapy
- Make sure your caregiver wears gloves when handling LONSURF
- Note that there is a packet inside the bottle that helps absorb moisture. Do not swallow this material
- Keep LONSURF out of the reach of children
- Store LONSURF at room temperature between 68°F and 77°F (20°C and 25°C)
- Don't store LONSURF with other medicines. Keep LONSURF in its own container
- If you store your tablets outside of the original container, any unused LONSURF tablets should be disposed of after 30 days

Contact your healthcare provider if:



- **You miss a dose.** Do not take additional doses to make up for the missed dose. Call your healthcare provider for instructions about what to do for a missed dose
- **You have leftover tablets.** Your healthcare provider or pharmacist will tell you how to dispose of them properly

IMPORTANT SAFETY INFORMATION

Before taking LONSURF, tell your healthcare provider about all of your medical conditions, including if you:

- Are breastfeeding or plan to breastfeed. It is not known if LONSURF passes into your breast milk. Do not breastfeed during treatment with LONSURF and for 1 day after your last dose of LONSURF

Tell your healthcare provider about all the prescription and over-the-counter medicines, vitamins, and herbal supplements you take.

What are the most common side effects?

The most common side effects of **LONSURF when used in combination with bevacizumab** include:

- Low blood counts
- Tiredness and weakness
- Nausea
- Certain abnormal liver function blood tests
- Decreased salt (sodium) in your blood
- Diarrhea
- Stomach-area (abdominal) pain
- Decreased appetite

The most common side effects of **LONSURF when used alone** include:

- Low blood counts
- Tiredness and weakness
- Nausea
- Decreased appetite
- Diarrhea
- Vomiting
- Stomach-area (abdominal) pain
- Fever

Tell your healthcare provider if you have nausea, vomiting, or diarrhea that gets worse or does not go away. These are not all of the possible side effects of LONSURF.

You can use a thermometer to check your temperature. Record your temperature, along with any side effects you have in the notes section starting on page 20. Make sure to discuss this information with your healthcare provider at your next appointment.



You can also call the Taiho Oncology 24/7 hotline with questions about, or to report, side effects with LONSURF at **1-844-US-TAIHO (1-844-878-2446)**. You may report side effects to the FDA at **1-800-FDA-1088**.

Please see Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets

How to manage side effects

Your healthcare provider may have ways to help manage some of the side effects of treatment. This could include adjusting your treatment plan by changing your dosage of LONSURF® (trifluridine and tipiracil) tablets or stopping treatment. After discussing any side effects, your healthcare provider may prescribe medications or recommend certain lifestyle changes or non-prescription medications that can help.

The following information may also be helpful to you in managing some of these side effects that may occur with LONSURF alone or in combination with bevacizumab while under the care of your healthcare provider.

This information is not meant to replace your healthcare provider's advice. Always discuss any side effects with your healthcare provider.



Abdominal pain

- Exercise regularly*
- Try to eat plenty of foods that are high in fiber such as fruits and vegetables
- Avoid foods that produce gas
- Try deep breathing, yoga, or other ways to relax. This can help with muscle tension, anxiety, and pain

*You should check with your doctor before beginning any exercise program.

IMPORTANT SAFETY INFORMATION

The **most common side effects of LONSURF when used alone** include low blood counts, tiredness and weakness, nausea, decreased appetite, diarrhea, vomiting, stomach-area (abdominal) pain, and fever.



Decreased appetite

- Try to eat soup if you do not feel like eating solid foods, or drink milkshakes, smoothies, and juice
- Choose foods that are high in calories and/or protein
- Being active may help you feel hungrier. Try going for a 15-minute walk, stretching, swimming, or riding a bike*



Diarrhea

- Try to eat or drink foods high in sodium and potassium, like bananas, oranges, peach and apricot nectar, and boiled or mashed potatoes
- Try to eat or drink low-fiber foods, including tender meats, tofu, eggs, fish, white bread, white rice, and fruit and vegetable juices
- Drink 8 to 12 cups of clear, room-temperature liquids slowly each day

*You should check with your doctor before beginning any exercise program.

Please see Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets



Nausea and vomiting

- Try to avoid foods that are greasy, fried, sweet, or spicy if they've made you feel sick after eating them
- Try to eat 5 or 6 small meals a day, instead of 3 big ones (this does not change your dosing schedule)
- Have food and drinks that are warm or cool instead of hot or cold
- Try sucking on ice cubes or taking small bites of ice pops or fruit ices (stop if the cold temperature bothers you)



Tiredness (fatigue/weakness)

- Do the things that are most important first each day. Don't overdo it
- Take time to rest and take short naps throughout the day
- Try to be active each day. Go for a 15-minute walk, practice yoga, or ride an exercise bike*
- Try adding bathing, reading, listening to music, or meditation to your bedtime routine to help you feel more relaxed
- Ask family members and friends for help with chores, driving to your appointments, shopping, and cooking

*You should check with your doctor before beginning any exercise program.

IMPORTANT SAFETY INFORMATION

The **most common side effects of LONSURF® (trifluridine and tipiracil) tablets when used in combination with bevacizumab** include low blood counts, tiredness and weakness, nausea, certain abnormal liver function blood tests, decreased salt (sodium) in your blood, diarrhea, stomach-area (abdominal) pain, and decreased appetite.

The questions below are designed to help you get the most out of your appointment with your healthcare provider.

- 1** **How are you feeling since your last appointment?**
 - Have you had any change in symptoms?
 - When did your symptoms start and how long have they been going on?

- 2** **Are you experiencing any side effects related to your treatment (for example, nausea, vomiting, diarrhea, or others)?**
 - Are these new side effects or ones that have become worse?
 - When did they start and how long have they been going on?

- 3** **Are there any changes to your medical history since your last appointment?**
 - Do you have any new diagnoses from another healthcare provider?
 - Are there any changes in other medications you're taking, including when, how often, and what dose?

- 4** **Are you experiencing any challenges in your life, or do you have any upcoming life events you're preparing for?**
 - What are these challenges or events?
 - Do you have any questions or concerns about how your symptoms or treatment may affect you during these events?

Please see Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets

Taiho Oncology Patient Support™

Taiho Oncology Patient Support offers personalized services to help patients, caregivers, and healthcare providers access Taiho Oncology products. This includes insurance coverage determination and help with medication affordability.



Personalized Support

- Benefits investigation, prior authorization assistance, and appeals assistance if needed
- Coordination of prescriptions with pharmacies
- One-on-one nurse educational support for patients available via opt-in at the time of enrollment



Patient Affordability Assistance

- \$0 co-pay program enrollment for eligible commercially insured patients
- Patient assistance program designed to provide free medication to eligible patients who are uninsured or underinsured
- Referrals to Medicare Part D Low-Income Subsidy (LIS)/Extra Help Program
- Referrals to third-party foundations for co-pay or other assistance based on eligibility and additional criteria

Eligible patients may pay \$0 per treatment cycle

CO-PAY ASSISTANCE PROGRAM

Potential

\$0 CO-PAY*

If you are eligible, the Taiho Oncology Co-Pay Program may help reduce your co-pay responsibility to \$0

 TAIHO ONCOLOGY  TAIHO ONCOLOGY
PATIENT SUPPORT
Supporting your treatment journey

Patients may be eligible if they:

- Have commercial prescription insurance coverage
- Use a specialty pharmacy
- Use a hospital outpatient pharmacy
- Receive medicine from a doctor's office

Patients may not be eligible if they:

- Are reimbursed under Medicaid, a Medicare drug benefit program, TRICARE, or other state or federal programs
- Reside outside of the US, Puerto Rico, or US territories



To learn more about the Taiho Oncology Patient Support Program, talk to your healthcare provider, call **1-844-TAIHO-4U** (1-844-824-4648), or visit [TaihoPatientSupport.com](https://www.TaihoPatientSupport.com).

Please see Important Safety Information throughout and full [Prescribing Information](#).

Lonsurf[®]
(trifluridine and tipiracil) tablets

TREATMENT WITH LONSURF



For more information, talk to your healthcare provider or visit [LONSURF.com](https://www.lonsurf.com)

IMPORTANT SAFETY INFORMATION

Tell your healthcare provider if you have nausea, vomiting, or diarrhea that is severe or that does not go away. These are not all of the possible side effects of LONSURF. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

LONSURF is a registered trademark of Taiho Pharmaceutical Co., Ltd., used under license by Taiho Oncology, Inc.



© TAIHO ONCOLOGY, INC. 04/2024 All rights reserved. LON-PM-US-1771 v3

Lonsurf[®]
(trifluridine and tipiracil) tablets

PATIENT INFORMATION
LONSURF® (LON-serf)
(trifluridine and tipiracil)
tablets

What is the most important information I should know about LONSURF?

Your healthcare provider should do blood tests before you receive LONSURF, at day 15 during treatment with LONSURF, and as needed to check your blood cell counts.

LONSURF may cause serious side effects, including:

Low blood cell counts. Low blood counts are common with LONSURF and can sometimes be severe and life-threatening. LONSURF can cause a decrease in your white blood cells, red blood cells, and platelets. Low white blood cells can make you more likely to get serious infections that could lead to death. Your healthcare provider may:

- lower your dose of LONSURF or stop LONSURF if you have low white blood cell or low platelet counts.

Tell your healthcare provider right away if you get any of the following signs and symptoms of infection during treatment with LONSURF:

- fever
- chills
- body aches

See “**What are the possible side effects of LONSURF?**” for more information about side effects.

What is LONSURF?

LONSURF is a prescription medicine used:

- alone or in combination with the medicine bevacizumab to treat adults with colorectal cancer:
 - that has spread to other parts of the body, **and**
 - who have been previously treated with certain chemotherapy medicines.
- alone to treat adults with a kind of stomach cancer called gastric cancer including adenocarcinoma of the gastroesophageal junction:
 - that has spread to other parts of the body, **and**
 - who have been previously treated with at least 2 types of treatment which included certain medicines.

It is not known if LONSURF is safe and effective in children.

Before you take LONSURF, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney or liver problems
- are pregnant or plan to become pregnant. LONSURF can harm your unborn baby.
For females who can become pregnant:
 - Your healthcare provider will do a pregnancy test before you start treatment with LONSURF.
 - You should use effective birth control during treatment with LONSURF and for at least 6 months after your last dose of LONSURF. (Talk to healthcare provider about methods of birth control that can be used during this time)
 - Tell your healthcare provider right away if you become pregnant.
- For males:**
 - You should use a condom during sex with female partners who are able to become pregnant during your treatment with LONSURF and for 3 months after your last dose of LONSURF. Tell your healthcare provider right away if your partner becomes pregnant while you are taking LONSURF.
- are breastfeeding or plan to breastfeed. It is not known if LONSURF passes into breast milk. Do not breastfeed during treatment with LONSURF and for 1 day after your last dose of LONSURF.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take LONSURF?

- Take LONSURF exactly as your healthcare provider tells you. LONSURF comes in two strengths. Your healthcare provider may prescribe both strengths for your prescribed dose.
- Take LONSURF 2 times a day with food.
- Swallow LONSURF tablets whole.
- Your caregiver should wear gloves when handling LONSURF tablets.

- If you vomit right after taking a dose, or miss a dose of LONSURF, do not take additional doses to make up for the vomited or missed dose. Call your healthcare provider for instructions about what to do for a missed dose.
- Wash your hands after handling the LONSURF tablets.

What are the possible side effects of LONSURF?

LONSURF may cause serious side effects, including:

- See “**What is the most important information I should know about LONSURF?**”

The most common side effects of LONSURF when used alone include:

- low blood counts
- tiredness and weakness
- nausea
- decreased appetite
- diarrhea
- vomiting
- stomach-area (abdominal) pain
- fever

The most common side effects of LONSURF when used in combination with bevacizumab include:

- low blood counts
- tiredness and weakness
- nausea
- certain abnormal liver function blood tests
- decreased salt (sodium) in your blood
- diarrhea
- stomach-area (abdominal) pain
- decreased appetite

Tell your healthcare provider if you have nausea, vomiting, or diarrhea that is severe or that does not go away. These are not all of the possible side effects of LONSURF. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store LONSURF?

- Store LONSURF at room temperature between 68°F and 77°F (20°C and 25°C).
- If you store LONSURF outside of the original bottle, throw away (dispose of) any unused LONSURF tablets after 30 days.
- Talk to your healthcare provider about how to safely dispose of LONSURF.

Keep LONSURF and all medicines out of the reach of children.

General information about the safe and effective use of LONSURF

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LONSURF for a condition for which it was not prescribed. Do not give LONSURF to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about LONSURF that is written for health professionals.

What are the ingredients in LONSURF?

Active ingredients: trifluridine and tipiracil hydrochloride

Other ingredients: lactose monohydrate, pregelatinized starch, stearic acid, hypromellose, polyethylene glycol, titanium dioxide, ferric oxide, and magnesium stearate

Imprinting ink: shellac, ferric oxide red, ferric oxide yellow, titanium dioxide, FD&C Blue No. 2 Aluminum Lake, carnauba wax, and talc.

Manufactured by: Taiho Pharmaceutical Co., Ltd., Japan

Manufactured for: Taiho Oncology, Inc., Princeton, NJ 08540 USA

LONSURF is a registered trademark of Taiho Pharmaceutical Co., Ltd. used under license by Taiho Oncology, Inc.

For more information, go to www.Lonsurf.com or call 1-844-878-2446.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF.

LONSURF (trifluridine and tipiracil) tablets, for oral use
Initial U.S. Approval: 2015

RECENT MAJOR CHANGES

Indications and Usage (1.1)	8/2023
Dosage and Administration (2)	8/2023
Warnings and Precaution (5.1)	8/2023

INDICATIONS AND USAGE

LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with:

- metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1)
- metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. (1.2)

DOSAGE AND ADMINISTRATION

- Recommended Dosage:** 35 mg/m²/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1)

DOSAGE FORMS AND STRENGTHS

Tablets:

- 15 mg trifluridine/6.14 mg tipiracil (3)
- 20 mg trifluridine/8.19 mg tipiracil (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

- Severe Myelosuppression:** Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1)
- Embryo-Fetal Toxicity:** Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.2, 8.1, 8.3)

ADVERSE REACTIONS

The most common adverse reactions or laboratory abnormalities for single agent LONSURF (≥10%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. (6.1)

The most common adverse reactions or laboratory abnormalities for LONSURF in combination with bevacizumab (≥20%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Taiho Oncology, Inc. at 1-844-878-2446 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Lactation:** Advise not to breastfeed. (8.2)
- Geriatric Use:** For LONSURF as a single agent, Grade 3 or 4 neutropenia, Grade 3 anemia and Grade 3 or 4 thrombocytopenia occurred more commonly in patients 65 years or older. (8.5) For LONSURF in combination with bevacizumab Grade 3 or 4 neutropenia and Grade 3 or 4 thrombocytopenia occurred more commonly in patients 65 years or older. (8.5)
- Hepatic Impairment:** Do not initiate LONSURF in patients with baseline moderate or severe hepatic impairment. (8.7)
- Renal Impairment:** Reduce LONSURF dose in patients with severe renal impairment. (8.6)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

Revised: 8/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Metastatic Colorectal Cancer
- 1.2 Metastatic Gastric Cancer

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dosage
- 2.2 Dosage Modifications for Adverse Reactions
- 2.3 Recommended Dosage for Renal Impairment

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Severe Myelosuppression
- 5.2 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Metastatic Colorectal Cancer
- 14.2 Metastatic Gastric Cancer

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Metastatic Colorectal Cancer

LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

1.2 Metastatic Gastric Cancer

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dosage of LONSURF as a single agent or in combination with bevacizumab is 35 mg/m² up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment.

Refer to the Prescribing Information for bevacizumab dosing information.

Instruct patients to swallow LONSURF tablets whole.

Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹

[Table 1](#) shows the calculated initial daily dose based on body surface area (BSA).

Table 1: Recommended Dosage According to Body Surface Area (BSA)

BSA (m ²)	Total daily dose (mg)	Dose (mg) administered twice daily	Tablets per dose	
			15 mg	20 mg
< 1.07	70	35	1	1
1.07 – 1.22	80	40	0	2
1.23 – 1.37	90	45	3	0
1.38 – 1.52	100	50	2	1
1.53 – 1.68	110	55	1	2
1.69 – 1.83	120	60	0	3
1.84 – 1.98	130	65	3	1
1.99 – 2.14	140	70	2	2
2.15 - 2.29	150	75	1	3
≥2.30	160	80	0	4

2.2 Dosage Modifications for Adverse Reactions

Obtain complete blood cell counts prior to and on Day 15 of each cycle [see *Warnings and Precautions (5.1)*].

Do not initiate the cycle of LONSURF until:

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mm³ or febrile neutropenia is resolved
- Platelets greater than or equal to 75,000/mm³
- Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1

Within a treatment cycle, withhold LONSURF for any of the following:

- Absolute neutrophil count (ANC) less than 500/mm³ or febrile neutropenia
- Platelets less than 50,000/mm³
- Grade 3 or 4 non-hematologic adverse reaction

After recovery, resume LONSURF after reducing the dose by 5 mg/m²/dose from the previous dose, if the following occur:

- Febrile neutropenia
- Uncomplicated Grade 4 neutropenia (which has recovered to greater than or equal to 1,500/mm³) or thrombocytopenia (which has recovered to greater than or equal to 75,000/mm³) that results in more than 1 week delay in start of next cycle

- Non-hematologic Grade 3 or Grade 4 adverse reaction except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or Grade 3 diarrhea responsive to antidiarrheal medication

A maximum of 3 dose reductions are permitted. Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 20 mg/m² orally twice daily. Do not escalate LONSURF dosage after it has been reduced.

Refer to the bevacizumab prescribing information for dose modifications for adverse reactions associated with bevacizumab.

2.3 Recommended Dosage for Renal Impairment

Severe Renal Impairment

In patients with severe renal impairment [creatinine clearance (CL_{cr}) of 15 to 29 mL/min as determined by the Cockcroft-Gault formula], the recommended dosage is 20 mg/m² (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle ([Table 2](#)) [*see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)*]. Reduce dose to 15 mg/m² twice daily in patients with severe renal impairment who are unable to tolerate a dose of 20 mg/m² twice daily ([Table 2](#)). Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 15 mg/m² twice daily.

Table 2: Recommended Dosage for Severe Renal Impairment According to BSA

BSA (m ²)	Total daily dose (mg)	Dose (mg) administered twice daily	Tablets per dose	
			15 mg	20 mg
For a dose of 20 mg/m² twice daily:				
< 1.14	40	20	0	1
1.14 – 1.34	50	25*	2 in the evening*	1 in the morning*
1.35 – 1.59	60	30	2	0
1.60 – 1.94	70	35	1	1
1.95 – 2.09	80	40	0	2
2.10 – 2.34	90	45	3	0
≥ 2.35	100	50	2	1
For a dose of 15 mg/m² twice daily:				
< 1.15	30	15	1	0
1.15 – 1.49	40	20	0	1
1.50 – 1.84	50	25*	2 in the evening*	1 in the morning*
1.85 – 2.09	60	30	2	0
2.10 – 2.34	70	35	1	1
≥ 2.35	80	40	0	2

* For a total daily dose of 50 mg, instruct patients to take 1 x 20-mg tablet in the morning and 2 x 15-mg tablets in the evening.

3 DOSAGE FORMS AND STRENGTHS

Tablets:

- 15 mg trifluridine/6.14 mg tipiracil: white, biconvex, round, film-coated, imprinted with '15' on one side, and '102' and '15 mg' on the other side, in gray ink.
- 20 mg trifluridine/8.19 mg tipiracil: pale red, biconvex, round, film-coated, imprinted with '20' on one side, and '102' and '20 mg' on the other side, in gray ink.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Severe Myelosuppression

In the 1114 patients who received LONSURF as a single agent, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (17%), thrombocytopenia (4%) and febrile neutropenia (3%). Three patients (0.3%) died due to neutropenic infection/sepsis; four other patients (0.5%) died due to septic shock. A total of 14% of patients received granulocyte-colony stimulating factors.

In the 246 patients who received LONSURF in combination with bevacizumab, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (52%), anemia (5%), thrombocytopenia (4%) and febrile neutropenia (0.4%). One patient (0.4%) died due to abdominal sepsis and two other patients (0.8%) died due to septic shock. A total of 29% of patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated.

Withhold LONSURF for severe myelosuppression and resume at the next lower dosage [*see Dosage and Administration (2.2)*].

5.2 Embryo-Fetal Toxicity

Based on animal studies and its mechanism of action, LONSURF can cause fetal harm when administered to a pregnant woman. Trifluridine/tipiracil caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when orally administered during gestation at dosage levels resulting in exposures lower than those achieved at the recommended dosage of 35 mg/m² twice daily. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with LONSURF and for at least 6 months after the final dose [*see Use in Specific Populations (8.1, 8.3)*].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Severe Myelosuppression [*see Warnings and Precautions (5.1)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the WARNINGS AND PRECAUTIONS section and below reflect exposure to LONSURF at the recommended dose in 533 patients with metastatic colorectal cancer in RECURSE, 246 patients with metastatic colorectal cancer treated with LONSURF as monotherapy in SUNLIGHT and 335 patients with metastatic gastric cancer in TAGS. Among the 1114 patients who received LONSURF as a single agent, 12% were exposed for 6 months or longer and 1% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities ($\geq 10\%$) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

Among the 246 patients with metastatic colorectal cancer treated with LONSURF in combination with bevacizumab in SUNLIGHT, 39% were exposed for 6 months or longer, and 14% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities ($\geq 20\%$) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite.

Metastatic Colorectal Cancer

LONSURF as a single agent

The safety of LONSURF was evaluated in RECURSE, a randomized (2:1), double-blind, placebo-controlled trial in patients with previously treated metastatic colorectal cancer [see *Clinical Studies (14.1)*]. Patients received LONSURF 35 mg/m²/dose (n=533) or placebo (n=265) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. In RECURSE, 12% of patients received LONSURF for more than 6 months and 1% of patients received LONSURF for more than 1 year.

The study population characteristics were: median age 63 years; 61% male; 57% White, 35% Asian, and 1% Black.

The most common adverse reactions or laboratory abnormalities ($\geq 10\%$ in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were anemia, neutropenia, asthenia/fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

In RECURSE, 3.6% of patients discontinued LONSURF for an adverse reaction and 14% of patients required a dose reduction. The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, fatigue, and diarrhea.

[Table 3](#) and [Table 4](#) list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in RECURSE.

Table 3: Adverse Reactions ($\geq 5\%$) in Patients Receiving LONSURF and at a Higher Incidence ($>2\%$) than in Patients Receiving Placebo in RECOURSE

Adverse Reactions	LONSURF (N=533)		Placebo (N=265)	
	All Grades (%)	Grades 3-4* (%)	All Grades (%)	Grades 3-4* (%)
General				
Asthenia/fatigue	52	7	35	9
Pyrexia	19	1.3	14	0.4
Gastrointestinal				
Nausea	48	1.9	24	1.1
Diarrhea	32	3	12	0.4
Vomiting	28	2.1	14	0.4
Abdominal pain	21	2.4	19	3.8
Stomatitis	8	0.4	6	0
Metabolism and nutrition				
Decreased appetite	39	3.6	29	4.9
Infections [†]	27	7	16	4.9
Nervous system				
Dysgeusia	7	0	2.3	0
Skin and subcutaneous tissue				
Alopecia	7	0	1.1	0

*No Grade 4 definition for nausea, abdominal pain, or fatigue in National Cancer Institute Common Terminology

[†]Incidence reflects 64 preferred terms in the Infections and Infestations system organ class.

Table 4: Select Laboratory Abnormalities in RECOURSE

Laboratory Parameter*	LONSURF		Placebo	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
Hematologic				
Anemia [†]	77	18	33	3
Neutropenia	67	38	0.8	0
Thrombocytopenia	42	5	8	0.4

* Worst Grade at least one grade higher than baseline, with percentages based on number of patients with post-baseline samples, which may be <533 (LONSURF) or 265 (placebo)

[†] One Grade 4 anemia adverse reaction based on clinical criteria was reported

In RECOURSE, pulmonary emboli occurred more frequently in LONSURF-treated patients (2%) compared to no patients on placebo.

LONSURF in combination with bevacizumab

The safety of LONSURF in combination with bevacizumab was evaluated in SUNLIGHT, an international, randomized, open label study in patients with previously treated metastatic colorectal cancer [see *Clinical Studies (14.1)*].

The study population characteristics were: median age 63 years (20 to 90 years); 52% male; 88% White, 1.4% Black, 0.2% Asian, 0.2% American Indian or Alaska Native, and 9.6% were unknown; and baseline ECOG performance status 0 (46%), 1 (54%), or 2 (0.2%).

Serious adverse reactions occurred in 25% of patients. The most frequent serious adverse reactions ($\geq 2\%$) were intestinal obstruction (2.8%), and COVID-19 (2%). Fatal adverse reactions occurred in 1.2% of patients who received LONSURF in combination with bevacizumab, including rectal fistula (0.4%), bowel perforation (0.4%) and atrial fibrillation (0.4%).

Permanent treatment discontinuation due to an adverse reaction occurred in 13% of patients. The adverse reaction which resulted in permanent treatment discontinuation in $\geq 2\%$ of patients was fatigue.

Dosage reductions due to an adverse reaction or laboratory abnormality occurred in 7% of patients. At least one dose reduction in 3.7% of patients was required for neutropenia.

Dosage interruptions due to an adverse reaction occurred in 11% of patients who received LONSURF in combination with bevacizumab. The adverse reaction that required dosage interruption in $\geq 2\%$ of patients was nausea.

The most common adverse reactions or laboratory abnormalities ($\geq 20\%$ in incidence) in patients treated with LONSURF in combination with bevacizumab were neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased aspartate aminotransferase, increased alanine aminotransferase, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite. [Table 5](#) and [Table 6](#) list the adverse reactions and laboratory abnormalities, respectively, observed in SUNLIGHT.

Table 5: Adverse Reactions (≥5%) in SUNLIGHT

Adverse Reactions	LONSURF + Bevacizumab (N=246) (%)		LONSURF (N=246) (%)	
	All Grades	Grade 3 or 4	All Grades	Grade 3 or 4
Gastrointestinal disorders				
Nausea	37	1.6	27	1.6
Diarrhea*	21	1.2	19	2.4
Abdominal pain*	20	2.8	18	3.7
Vomiting*	19	0.8	15	1.6
Stomatitis*	13	<0.4	4.1	0
Constipation	11	0	11	0.8
General disorders and administration site conditions				
Fatigue*	45	5	37	8
Pyrexia	4.9	0	6	0.4
Infections and infestations*	31	8	24	8
Metabolism and nutrition disorders				
Decreased appetite	20	<0.8	15	1.2
Musculoskeletal and connective tissue disorders				
Musculoskeletal pain*	18	1.2	11	2
Nervous system disorder				
Headache	8	0	3.7	0
Vascular disorders				
Hypertension*	11	6	2	1.2
Hemorrhage*	10	1.2	3.7	0.8
Renal and urinary disorders				
Proteinuria	6	0.8	1.2	0

*Represents a composite of multiple related terms

Table 6: Select Laboratory Abnormalities ($\geq 10\%$) in SUNLIGHT

Laboratory parameters	LONSURF + Bevacizumab ^a		LONSURF ^a	
	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
Hematology				
Neutrophils decreased	80	52	68	39
Hemoglobin decreased	68	5	73	11
Platelets decreased	54	4.1	29	0.8
Chemistry				
Aspartate aminotransferase increased	34	2.1	28	1.2
Alanine aminotransferase increased	33	3.3	23	0.4
Alkaline phosphatase increased	31	0.8	36	1.2
Sodium decreased	25	2.1	20	3.3
Potassium increased	17	0	15	0
Potassium decreased	12	0.8	12	2.5
Creatinine increased	12	0.8	15	0

^aEach test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LONSURF + bevacizumab group (n=242 patients) and LONSURF group (range: 240 to 242 patients).

Metastatic Gastric Cancer

The safety of LONSURF was evaluated in TAGS, an international, randomized (2:1), double-blind, placebo-controlled trial in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who were previously treated with at least 2 prior chemotherapy regimens for advanced disease [see *Clinical Studies (14.2)*]. Previous treatments must have included a fluoropyrimidine, a platinum, and either a taxane or irinotecan. Patients with HER2/neu-positive tumors must have received prior HER2/neu-targeted therapy, if available. Adjuvant chemotherapy could be counted as one prior regimen in patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy. Patients received LONSURF 35 mg/m²/dose (n=335) or placebo (n=168) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle with best supportive care. In TAGS, 10% of patients received LONSURF for more than 6 months and 0.9% of patients received LONSURF for more than 1 year.

The study population characteristics were: median age 63 years (24 to 89 years); 73% male; 70% White, 16% Asian, and 1% Black.

The most common adverse reactions or laboratory abnormalities ($\geq 10\%$ in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were neutropenia, anemia, nausea, decreased appetite, thrombocytopenia, vomiting, and diarrhea.

In TAGS, 13% of patients discontinued LONSURF for an adverse reaction and 11% of patients required a dose reduction. The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, and diarrhea.

Table 7 and 8 list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in TAGS.

Table 7: Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in TAGS

Adverse Reactions	LONSURF (N=335)		Placebo (N=168)	
	All Grades (%)	Grades 3-4* (%)	All Grades (%)	Grades 3-4* (%)
Gastrointestinal				
Nausea	37	3	32	3
Vomiting	25	4	20	2
Diarrhea	23	3	14	2
Metabolism and nutrition				
Decreased appetite	34	9	31	7
Infections[†]	23	5	16	5

*No Grade 4 definition for nausea or fatigue in NCI CTCAE, version 4.03.

[†]Incidence reflects 46 preferred terms in the Infections and Infestations system organ class.

Table 8: Laboratory Abnormalities in TAGS

Laboratory Parameter*	LONSURF		Placebo	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
Hematologic				
Neutropenia	66	38	4	0
Anemia [†]	63	19	38	7
Thrombocytopenia	34	6	9	0

* Worst Grade at least one Grade higher than baseline, with percent based on number of patients with post-baseline samples which may be <335 (LONSURF) or 168 (placebo)

[†] Anemia: No Grade 4 definition in CTCAE, v4.03

In TAGS, pulmonary emboli occurred more frequently in LONSURF-treated patients (3.1%) compared to 1.8% for patients on placebo.

Additional Clinical Experience

Interstitial lung disease was reported in 15 (0.2%) patients, 3 of which were fatal, among approximately 7,000 patients exposed to LONSURF in clinical studies and clinical practice settings in Asia.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on animal data and its mechanism of action [see *Clinical Pharmacology (12.2)*], LONSURF can cause fetal harm. LONSURF caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when given during gestation at doses resulting in exposures lower than or similar to human exposures at the recommended clinical dose (see Data). There are no available data on LONSURF use in pregnant women. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Trifluridine/tipiracil was administered orally once daily to female rats during organogenesis at dose levels of 15, 50, and 150 mg/kg [trifluridine (FTD) equivalent]. Decreased fetal weight was observed at FTD doses ≥ 50 mg/kg (approximately 0.33 times the FTD exposure at the clinical dose of 35 mg/m² twice daily). At the FTD dose of 150 mg/kg (approximately 0.92 times the FTD exposure at the clinical dose of 35 mg/m² twice daily) embryoletality and structural anomalies (kinked tail, cleft palate, ectrodactyly, anasarca, alterations in great vessels, and skeletal anomalies) were observed.

8.2 Lactation

Risk Summary

There are no data on the presence of trifluridine, tipiracil or its metabolites in human milk or its effects on the breastfed child or on milk production. In nursing rats, trifluridine and tipiracil or their metabolites were present in breast milk (*see Data*). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Data

Radioactivity was excreted in the milk of nursing rats dosed with trifluridine/tipiracil containing ¹⁴C-FTD or ¹⁴C-tipiracil (TPI). Levels of FTD-derived radioactivity were as high as approximately 50% of the exposure in maternal plasma an hour after dosing with trifluridine/tipiracil and were approximately the same as those in maternal plasma for up to 12 hours following dosing. Exposure to TPI-derived radioactivity was higher in milk than in maternal plasma beginning 2 hours after dosing and continuing for at least 12 hours following administration of trifluridine/tipiracil.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating LONSURF [see *Use in Specific Populations (8.1)*].

Contraception

LONSURF can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations (8.1)*].

Females

Advise females of reproductive potential to use effective contraception during treatment with LONSURF and for at least 6 months after the final dose.

Males

Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose [see *Nonclinical Toxicology (13.1)*].

8.4 Pediatric Use

Safety and effectiveness of LONSURF in pediatric patients have not been established.

Juvenile Animal Toxicity Data

Dental toxicity including whitening, breakage, and malocclusion (degeneration and disarrangement in the ameloblasts, papillary layer cells and odontoblasts) were observed in rats treated with trifluridine/tipiracil at doses ≥ 50 mg/kg (approximately 0.33 times the exposure at the clinical dose of 35 mg/m² twice daily).

8.5 Geriatric Use

Of the 1114 patients with metastatic colorectal cancer or gastric cancer who received single agent LONSURF in clinical studies, 45% were 65 years of age or over, and 11% were 75 and over. In the 246 patients who received LONSURF in combination with bevacizumab; 41% were 65 years of age or over, and 10% were 75 and over. While these studies were not designed to detect a difference in efficacy, no overall differences were observed in patients 65 or older versus younger patients with either LONSURF as a single agent or LONSURF in combination with bevacizumab.

Patients 65 years of age or older who received LONSURF as a single agent had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (20% vs 14%), and Grade 3 or 4 thrombocytopenia (6% vs 3%). Patients 65 years of age or older who received LONSURF in combination with bevacizumab had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (60% vs 46%) and Grade 3 or 4 thrombocytopenia (5% vs 4%).

8.6 Renal Impairment

No dose adjustment is recommended for patients with mild or moderate renal impairment (CL_{cr} of 30 to 89 mL/min as determined by the Cockcroft-Gault formula). Reduce the dose of LONSURF for patients with severe renal impairment (CL_{cr} of 15 to 29 mL/min) [see *Dosage and Administration* (2.3)]. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with end stage renal disease.

8.7 Hepatic Impairment


No adjustment to the starting dosage of LONSURF is recommended for patients with mild hepatic impairment. Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin >1.5 times ULN and any AST) hepatic impairment [see *Clinical Pharmacology* (12.3)].

11 DESCRIPTION

LONSURF contains trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5.

Trifluridine

Trifluridine, a nucleoside metabolic inhibitor, is described chemically as 2'-deoxy-5-(trifluoromethyl) uridine and has the following structural formula:




Trifluridine has a molecular formula C₁₀H₁₁F₃N₂O₅ and a molecular weight of 296.20.

Trifluridine is a white crystalline powder, soluble in water, ethanol, 0.01 mol/L hydrochloric acid, 0.01 mol/L sodium hydroxide solution; freely soluble in methanol, acetone; sparingly soluble in 2-propanol, acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether.

Tipiracil hydrochloride

Tipiracil hydrochloride, a thymidine phosphorylase inhibitor, is described chemically as 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1*H*,3*H*)-dione monohydrochloride or 2,4(1*H*,3*H*)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-, hydrochloride (1:1) and has the following structural formula:



Tipiracil hydrochloride has a molecular formula $C_9H_{11}ClN_4O_2 \cdot HCl$ and a molecular weight of 279.12. Tipiracil hydrochloride is a white crystalline powder, soluble in water, 0.01 mol/L hydrochloric acid, and 0.01 mol/L sodium hydroxide; slightly soluble in methanol; very slightly soluble in ethanol; and practically insoluble in acetonitrile, 2-propanol, acetone, diisopropyl ether, and diethyl ether.

LONSURF (trifluridine and tipiracil) tablets for oral use contain 15 mg of trifluridine and 6.14 mg of tipiracil equivalent to 7.065 mg of tipiracil hydrochloride or 20 mg of trifluridine and 8.19 mg of tipiracil equivalent to 9.420 mg of tipiracil hydrochloride.

LONSURF tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, stearic acid, hypromellose, polyethylene glycol, titanium dioxide, ferric oxide, and magnesium stearate. The tablets are imprinted with ink containing shellac, ferric oxide red, ferric oxide yellow, titanium dioxide, FD&C Blue No. 2 Aluminum Lake, carnauba wax, and talc.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase.

Following uptake into cancer cells, trifluridine is incorporated into DNA, interferes with DNA synthesis and inhibits cell proliferation. Trifluridine/tipiracil demonstrated anti-tumor activity against *KRAS* wild-type and mutant human colorectal cancer xenografts in mice.

12.2 Pharmacodynamics

Cardiac Electrophysiology

LONSURF administered to 42 patients with advanced solid tumors at the recommended dosage had no large effect (i.e. >20 ms) in the mean QTc interval when compared to placebo and no exposure-QT relationship was identified. Two of 42 patients (4.8%) had QTc >500 msec and 2.4% had a QTc increase from baseline >60 msec.

12.3 Pharmacokinetics

After twice daily dosing of LONSURF, systemic exposure (AUC) of trifluridine increased more than dose-proportionally over the dose range of 15 mg/m² (0.43 times the recommended dose) to 35 mg/m².

The accumulation of trifluridine was 3-fold for AUC_{0-12hr} and 2-fold for C_{max} at steady state while no accumulation was observed for tipiracil.

Administration of a single dose of LONSURF 35 mg/m² increased the mean AUC_{0-last} of trifluridine by 37-fold and C_{max} by 22-fold with reduced variability compared to administration of a single dose of trifluridine 35 mg/m² alone.

Absorption

Following a single oral administration of LONSURF at 35 mg/m² in patients with cancer, the mean time to peak plasma concentration (T_{max}) of trifluridine was around 2 hours.

Food Effect

A standardized high-fat, high-calorie meal decreased trifluridine C_{max}, tipiracil C_{max} and AUC by approximately 40%, but did not change trifluridine AUC compared to those in a fasting state in patients with cancer following administration of a single dose of LONSURF 35 mg/m².

Distribution

Trifluridine mainly binds to human serum albumin. The in vitro protein binding of trifluridine in human plasma is >96%, independent of drug concentration and presence of tipiracil. Plasma protein binding of tipiracil is below 8%.

Elimination

After administration of LONSURF 35 mg/m², the mean elimination half-life (t_{1/2}) of trifluridine was 1.4 hours and of tipiracil was 2.1 hours after a single dose. The mean elimination half-life at steady state of trifluridine was 2.1 hours and of tipiracil was 2.4 hours.

Metabolism

Trifluridine and tipiracil are not metabolized by cytochrome P450 (CYP) enzymes. Trifluridine is mainly eliminated by metabolism via thymidine phosphorylase to form an inactive metabolite, 5-(trifluoromethyl) uracil (FTY). No other major metabolites were detected in plasma or urine.

Excretion

After single oral administration of LONSURF (60 mg) with [¹⁴C]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose. The majority of recovered radioactivity was eliminated into urine (55% of the dose) as FTY and trifluridine glucuronide isomers within 24 hours and the excretion into feces and expired air was <3% for both. The unchanged trifluridine was <3% of administered dose recovered in the urine and feces.

After single oral administration of LONSURF (60 mg) with [¹⁴C]-tipiracil hydrochloride, recovered radioactivity was 77% of the dose, which consisted of 27% urinary excretion and 50% fecal excretion. Tipiracil was the major component and 6-HMU was the major metabolite in urine, and feces.

Specific Populations

Based on the population pharmacokinetic analysis, there is no clinically relevant effect of age, sex, or race (White or Asian) on the pharmacokinetics of trifluridine or tipiracil.

Patients with Renal Impairment

In a dedicated renal impairment study, all patients received LONSURF 35 mg/m² twice daily except for patients with severe renal impairment who received 20 mg/m² twice daily. Mild renal impairment (CLcr of 60 to 89 mL/min as determined by the Cockcroft-Gault formula) had no clinically important effect on steady-state AUC_{0-last} of trifluridine and tipiracil. Moderate renal impairment (CLcr of 30 to 59 mL/min) increased steady-state AUC_{0-last} of trifluridine by 56% and tipiracil by 139% compared to normal renal function (CLcr ≥ 90 mL/min). Severe renal impairment (CLcr of 15 to 29 mL/min) increased the dose-normalized steady-state AUC_{0-last} of trifluridine by 140% and tipiracil by 614% compared to normal renal function. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with end stage renal disease.

Patients with Hepatic Impairment

No clinically important differences in the mean exposures of trifluridine and tipiracil were observed between patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN or total bilirubin <1 to 1.5 times ULN and any AST) to moderate hepatic impairment (total bilirubin >1.5 to 3 times ULN and any AST) and patients with normal hepatic function (total bilirubin and AST ≤ ULN); however, 5 of 6 patients with moderate hepatic impairment experienced Grade 3 or 4 increased bilirubin levels. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with severe hepatic impairment [*see Dosage Modifications (2.2), Use in Specific Populations (8.6)*].

Drug Interaction Studies

In vitro studies indicated that trifluridine, tipiracil, and FTY did not inhibit the CYP enzymes and had no inductive effect on CYP1A2, CYP2B6, or CYP3A4/5.

In vitro studies indicated that trifluridine was not an inhibitor of or substrate for human uptake and efflux transporters.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies evaluating the carcinogenic potential of trifluridine/tipiracil in animals have been performed. Trifluridine/tipiracil was genotoxic in a reverse mutation test in bacteria, a chromosomal aberration test in mammalian-cultured cells, and a micronucleus test in mice.

Animal studies did not indicate an effect of trifluridine/tipiracil on male fertility in rats. Dose-related increases in the corpus luteum count and implanted embryo count were observed, but female fertility was not affected.

14 CLINICAL STUDIES

14.1 Metastatic Colorectal Cancer

Previously treated metastatic colorectal cancer (single agent LONSURF)

RECOURSE

The efficacy of LONSURF was evaluated in RECOURSE (NCT01607957), an international, randomized, double-blind, placebo-controlled study conducted in patients with previously treated metastatic colorectal cancer (mCRC). Key eligibility criteria included prior treatment with at least 2 lines of standard chemotherapy for metastatic CRC, ECOG performance status (PS) 0-1, absence of brain metastasis, and absence of ascites requiring drainage in the past four weeks. Patients were randomized 2:1 to receive LONSURF 35 mg/m² or matching placebo orally twice daily after meals on Days 1-5 and 8-12 of each 28-day cycle until disease progression or unacceptable toxicity. Randomization was stratified by KRAS status (wild-type vs. mutant), time since diagnosis of first metastasis (<18 months vs. ≥ 18 months), and region (Japan vs. US, Europe and Australia). The major efficacy outcome measure was overall survival (OS) and an additional efficacy outcome measure was progression-free survival (PFS).

A total of 800 patients were randomized to LONSURF (N=534) with best supportive care (BSC) or matching placebo (N=266) plus BSC. The median age was 63 years, 61% were male, 58% and 35% were White and Asian respectively, and all patients had baseline ECOG PS of 0 or 1. The primary site of disease was colon (62%) or rectum (38%). KRAS status was wild-type (49%) or mutant (51%) at study entry. All patients received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. All but one patient received bevacizumab and all but two patients with KRAS wild-type tumors received panitumumab or cetuximab.

Efficacy results are summarized in [Table 9](#) and [Figure 1](#).

Table 9: Efficacy Results from RECOURSE


	LONSURF (N=534)	Placebo (N=266)
Overall Survival		
Number of deaths, N (%)	364 (68)	210 (79)
Median OS (months) ^a (95% CI) ^b	7.1 (6.5, 7.8)	5.3 (4.6, 6.0)
Hazard ratio (95% CI)	0.68 (0.58, 0.81)	
p-value ^c	<0.001	
Progression-Free Survival		
Number of events, N (%)	472 (88)	251 (94)
Hazard ratio (95% CI)	0.47 (0.40, 0.55)	
p-value ^c	<0.001	

^a Kaplan-Meier estimates

^b Methodology of Brookmeyer and Crowley

^c Stratified log-rank test (strata: KRAS status, time since diagnosis of first metastasis, region), 2-sided

Figure 1: Kaplan-Meier Curves of Overall Survival in RECOURSE



Previously treated metastatic colorectal cancer (LONSURF in combination with bevacizumab)

SUNLIGHT

The efficacy of LONSURF in combination with bevacizumab was evaluated in SUNLIGHT (NCT 04737187), an international, randomized (1:1), open label study in patients with previously treated metastatic colorectal cancer. Patients were required to have received no more than 2 prior treatments for advanced disease, including a fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody (optional) and an anti-EGFR monoclonal antibody for patients with RAS wild-type. Other key eligibility criteria included ECOG performance status (PS) 0-1, absence of symptomatic brain metastases, absence of ascites requiring drainage in the past 4 weeks, absence of uncontrolled hypertension, absence of non-healing wound, and absence of deep venous thromboembolic event in the past 4 weeks. Patients were randomized to receive LONSURF 35 mg/m² administered orally twice daily on Days 1 to 5 and 8 to 12 of each 28-day cycle with or without bevacizumab 5 mg/kg administered intravenously every 2 weeks (on Day 1 and Day 15) of each 4-week cycle until disease progression or unacceptable toxicity. Randomization was stratified by geographic region (North America, European Union, Rest of the World), time since diagnosis of metastatic disease (<18 months, ≥18 months) and RAS status (wild-type, mutant). The major efficacy outcome was overall survival (OS), and an additional efficacy outcome measure was progression-free survival (PFS).

A total of 492 patients were randomized to receive LONSURF in combination with bevacizumab (N=246) or LONSURF as a single agent (N=246). The trial population characteristics were as follows: median age 63 years, 52% male, 88% White, 1.4% Black, 0.2% Asian, 0.2% American Indian or Alaska Native, and 9.6% were unknown, 46% had ECOG PS 0 and 54% had ECOG PS 1. The primary site of disease was colon (73%) or rectum (27%). Seventy-one percent of patients had a RAS mutant status. A total of 92% of patients received 2 prior anticancer treatment

regimens for advanced CRC; all patients received prior fluoropyrimidine; 99.8% of patients received prior irinotecan; 98% of patients received prior oxaliplatin. Among all 492 treated patients, 76% received prior anti-VEGF treatment, and 72% received an anti-VEGF monoclonal antibody. Among the 142 patients with RAS wild-type mCRC, 94% received prior anti-EGFR monoclonal antibody.

Efficacy results are summarized in [Table 10](#) and [Figure 2](#).

Table 10: Efficacy Results from SUNLIGHT

	LONSURF plus Bevacizumab (N=246)	LONSURF (N=246)
Overall survival		
Number of deaths, N (%)	148 (60)	183 (74)
Median OS (months) ^a (95% CI) ^b	10.8 (9.4, 11.8)	7.5 (6.3, 8.6)
Hazard ratio (95% CI) ^c	0.61 (0.49, 0.77)	
p-value ^d	<0.001	
Progression-free survival (per investigator)		
Number of events N (%)	206 (84)	236 (96)
Median PFS (months) ^a (95% CI) ^b	5.6 (4.5, 5.9)	2.4 (2.1, 3.2)
Hazard ratio (95% CI) ^d	0.44 (0.36, 0.54)	
p-value ^d	<0.001	


a Kaplan-Meier estimates

b Methodology of Brookmeyer and Crowley

c Stratified proportional hazards model (strata: region, time since first metastasis diagnosis, RAS status)

d Stratified log-rank test (strata: region, time since first metastasis diagnosis, RAS status), 1-sided p-value

Figure 2: Kaplan-Meier Curves of Overall Survival in SUNLIGHT



Number of patients at risk:

Lonsurf+Bevacizumab	246	244	239	230	217	203	183	160	149	131	119	104	88	69	52	37	24	13	2	0	0
Lonsurf	246	242	230	205	184	163	143	120	108	95	85	76	63	44	24	16	10	5	2	1	0

14.2 Metastatic Gastric Cancer

The efficacy of LONSURF was evaluated in TAGS (NCT02500043), an international, randomized, double-blind, placebo-controlled study in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior regimens for advanced disease. Previous treatments must have included a fluoropyrimidine, a platinum, and either a taxane or irinotecan. Patients with HER2/neu-positive tumors must have received prior HER2/neu-targeted therapy, if available. Adjuvant chemotherapy could be counted as one prior regimen in patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy. Other key eligibility criteria included ECOG performance status (PS) 0 or 1. Patients were randomized 2:1 to receive LONSURF 35 mg/m² orally twice daily on Days 1-5 and 8-12 of each 28-day cycle with best supportive care (BSC) or matching placebo with BSC until disease progression or unacceptable toxicity. Randomization was stratified by ECOG PS at baseline (0 vs. 1), prior ramucirumab (yes vs. no), and geographic region (Japan vs. rest of world). The major efficacy outcome measure was OS and an additional outcome measure was PFS.

A total of 507 patients were randomized to LONSURF (N=337) or placebo (N=170). The median age was 63 years, 73% were male, 70% and 16% were White and Asian respectively, and 38% had a baseline ECOG PS of 0. Seventy-one percent of patients had gastric tumors, 29% had GEJ tumors, and two patients had gastric/GEJ tumors. All patients received platinum-based chemotherapy, 99% received fluoropyrimidine-based therapy, 91% received a taxane, 55% received irinotecan, and 33% received ramucirumab. The HER2 status was negative in 62%,

positive in 19%, and unknown in 20% of patients. Among the 94 patients with HER2 positive tumors, 89% received prior anti-HER2 therapy.

Efficacy results are summarized in [Table 11](#) and [Figure 3](#).

Table 11: Efficacy Results from TAGS


	LONSURF (N=337)	Placebo (N=170)
Overall Survival		
Number of deaths, N (%)	244 (72)	140 (82)
Median OS (months) ^a (95% CI) ^b	5.7 (4.8, 6.2)	3.6 (3.1, 4.1)
Hazard ratio (95% CI)	0.69 (0.56, 0.85)	
p-value ^c	0.0006	
Progression-Free Survival		
Number of events, N (%)	287 (85)	156 (92)
Hazard ratio (95% CI)	0.56 (0.46, 0.68)	
p-value ^c	<0.0001	

^a Kaplan-Meier estimates

^b Methodology of Brookmeyer and Crowley

^c Stratified log-rank test (strata: ECOG PS, prior ramucirumab treatment, region), 2-sided

Figure 3: Kaplan-Meier Curves of Overall Survival in TAGS



15 REFERENCES

1. “OSHA Hazardous Drugs”. OSHA.
<http://www.osha.gov/SLTC/hazardousdrugs/index.html>

16 HOW SUPPLIED/STORAGE AND HANDLING

LONSURF 15 mg/6.14 mg tablets are supplied as white, biconvex, round, film-coated tablet, imprinted with ‘15’ on one side, and ‘102’ and ‘15 mg’ on the other side, in gray ink. The tablets are packaged in HDPE bottles with child resistant closures in the following presentations:

- 20 count: NDC 64842-1025-1
- 40 count: NDC 64842-1025-2
- 60 count: NDC 64842-1025-3

LONSURF 20 mg/8.19 mg tablets are supplied as pale red, biconvex, round, film-coated tablet, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in gray ink. The tablets are packaged in HDPE bottles with child resistant closures in the following presentations:

- 20 count: NDC 64842-1020-1
- 40 count: NDC 64842-1020-2
- 60 count: NDC 64842-1020-3

Store at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹
If stored outside of original bottle, discard after 30 days.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling ([Patient Information](#)).

Severe Myelosuppression

Advise patients to immediately contact their healthcare provider if they experience signs or symptoms of infection and advise patients to keep all appointments for blood tests [*see Warnings and Precautions (5.1)*].

Gastrointestinal Toxicity

Advise patients to contact their healthcare provider for severe or persistent nausea, vomiting, diarrhea, or abdominal pain [*see Adverse Reactions (6.1)*].

Administration Instructions

Advise patients that LONSURF is available in two strengths and they may receive both strength tablets to provide the prescribed dosage.

Advise patients to take LONSURF with food [*see Dosage and Administration (2.1)*].

Advise patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

Advise patients that anyone else who handles their medication should wear gloves [*see References (15)*].

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [*see Warnings and Precautions (5.2), Use in Specific Populations (8.3)*].

Advise female patients of reproductive potential to use effective contraception during treatment with LONSURF and for at least 6 months after the final dose [*see Warnings and Precautions (5.2), Use in Specific Populations (8.3)*].

Advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose [*see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)*].

Lactation

Advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose [*see Use in Specific Populations (8.2)*].

Manufactured by: Taiho Pharmaceutical Co., Ltd., Japan

Manufactured for: Taiho Oncology, Inc., Princeton, NJ 08540 USA

LONSURF is a registered trademark of Taiho Pharmaceutical Co., Ltd. used under license by Taiho Oncology, Inc.